<p>TransMedics Group, Inc.（納斯達克代碼：TMDX - 獲取免費報告）的股票在週一交易中上漲了 6.8%，此前華爾街 Zen 將該股票的評級從持有上調至買入。該股票最高交易價格為 130.70 美元，最後交易價格為 128.76 美元。在交易過程中，約有 501,417 股易手，較平均每日交易量 1,355,177 股下降了 63%。該股票此前收盤價為 120.55 美元。</p>
<ul>
<li>中型股的奇蹟：三隻在五月份超越銷售預期的股票</li>
</ul>
<p>TMDX 已經成為其他多份研究報告的主題。Needham &amp; Company LLC 在 6 月 17 日的報告中重申了對 TransMedics Group 股票的 “持有” 評級。Oppenheimer 在 6 月 17 日的報告中將 TransMedics Group 的股票目標價從 130.00 美元上調至 150.00 美元，並給予該公司 “跑贏大盤” 的評級。摩根士丹利在週五的報告中將 TransMedics Group 的股票目標價從 115.00 美元上調至 123.00 美元，並給予該公司 “同等權重” 的評級。Canaccord Genuity Group 在 7 月 15 日的報告中將 TransMedics Group 的股票目標價從 129.00 美元上調至 142.00 美元，並給予該公司 “買入” 的評級。最後，Piper Sandler 在 6 月 4 日的報告中重申了 “超配” 評級，並將 TransMedics Group 的股票目標價設定為 145.00 美元（之前為 125.00 美元）。三位研究分析師對該股票給予了持有評級，六位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為 123.00 美元。</p>
<p>獲取 <strong>TransMedics Group</strong> 的提醒：</p>
<p><strong>查看我們關於 TMDX 的最新報告</strong></p>
<h2>內部人士下注</h2>
<ul>
<li>三隻在 2025 年表現優異的醫療技術股票</li>
</ul>
<p>在其他 TransMedics Group 的新聞中，董事 David Weill 在 5 月 23 日的交易中出售了 732 股該公司的股票。股票以平均價格 123.88 美元出售，總交易額為 90,680.16 美元。出售後，該董事在公司中持有 12,134 股，價值約為 1,503,159.92 美元。這筆交易代表了其持股比例的 5.69% 下降。該交易已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。此外，內部人士 Anil P. Ranganath 在 6 月 9 日的交易中出售了 686 股該公司的股票。股票以平均價格 139.80 美元出售，總交易額為 95,902.80 美元。出售後，該內部人士在公司中持有 13,955 股，價值約為 1,950,909 美元。這筆交易代表了其持股比例的 4.69% 下降。該出售的披露信息可以在這裏找到。在過去 90 天內，內部人士已出售 12,418 股公司股票，價值 1,512,613 美元。公司內部人士持有公司股票的 7.00%。</p>
<h2>機構投資者對 TransMedics Group 的看法</h2>
<p>機構投資者和對沖基金最近調整了對該股票的持有。Opal Wealth Advisors LLC 在第二季度購買了 TransMedics Group 的新股份，價值約為 26,000 美元。Sound Income Strategies LLC 在第二季度購買了 TransMedics Group 的新股份，價值約為 48,000 美元。NBC Securities Inc.在第一季度購買了 TransMedics Group 的新股份，價值約為 25,000 美元。Smartleaf Asset Management LLC 在第一季度將其在 TransMedics Group 的持股比例提高了 44.3%。Smartleaf Asset Management LLC 現在持有 440 股該公司的股票，價值 30,000 美元，此前在上個季度又購買了 135 股。最後，Atlas Capital Advisors Inc.在第四季度購買了 TransMedics Group 的新股份，價值約為 31,000 美元。機構投資者持有公司 99.67% 的股票。</p>
<h2>TransMedics Group 股票表現</h2>
<ul>
<li>三隻交易者喜愛的高增長股票，投資者應關注</li>
</ul>
<p>該股票的市值為 44.4 億美元，市盈率為 67.48，貝塔值為 2.09。該公司的債務與股本比率為 1.61，流動比率為 9.86，速動比率為 9.17。該公司的 50 日移動平均價格為 124.51 美元，200 日移動平均價格為 95.50 美元。</p>
<p>TransMedics Group（納斯達克代碼：TMDX - 獲取免費報告）最近在 7 月 30 日宣佈了其季度財報。該公司報告每股收益為 0.92 美元，超出市場共識預期的 0.48 美元，超出幅度為 0.44 美元。TransMedics Group 的淨利潤率為 13.49%，股本回報率為 28.02%。該公司季度收入為 1.5737 億美元，而分析師預期為 1.4664 億美元。去年同期，該公司每股收益為 0.35 美元。TransMedics Group 的季度收入同比增長 37.7%。賣方分析師預計 TransMedics Group, Inc.在當前財政年度將發佈 1 美元的每股收益。</p>
<h2>關於 TransMedics Group</h2>
<p>（獲取免費報告）</p>
<p>TransMedics Group, Inc.是一家商業階段的醫療技術公司，致力於為美國及國際上的終末期器官衰竭患者轉變器官移植治療。該公司提供器官護理系統（OCS），這是一種便攜式器官灌注、優化和監測系統，利用其專有和定製技術在人體外複製接收器官的近生理條件。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票超過 TransMedics Group</li>
<li>這些液化天然氣股票是否準備迎來反彈？</li>
<li>三個令人驚訝的盈利贏家改變了他們的市場敍事</li>
<li>如何投資 FAANG 股票</li>
<li>48 小時內的兩筆交易如何改變了 Joby Aviation 的一切</li>
<li>深入瞭解買賣差價</li>
<li>五隻塑造明天世界的股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 TransMedics Group 嗎？</h2>
<p>在你考慮 TransMedics Group 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 TransMedics Group 並不在名單上。</p>
<p>雖然 TransMedics Group 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TMDX

<p>TransMedics Group（納斯達克代碼：TMDX）股價上漲 6.8%，因華爾街 Zen 將該股票評級從持有上調至買入。該股最高達到 130.70 美元，最終收於 128.76 美元，交易量下降了 63%。分析師的評級各異，其中三位持有，六位買入，一位強烈買入。公司報告每股收益為 0.92 美元，超出預期，營收為 1.5737 億美元，同比增長 37.7%。內部人士近期出售了部分股份，機構投資者持有 99.67% 的股份</p>

<p>Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) were up 6.8% during trading on Monday after Wall Street Zen upgraded the stock from a hold rating to a buy rating. The stock traded as high as $130.70 and last traded at $128.76. Approximately 501,417 shares changed hands during trading, a decline of 63% from the average daily volume of 1,355,177 shares. The stock had previously closed at $120.55.</p>
<div class="lb-trans"><p>TransMedics Group, Inc.（納斯達克代碼：TMDX - 獲取免費報告）的股票在週一交易中上漲了 6.8%，此前華爾街 Zen 將該股票的評級從持有上調至買入。該股票最高交易價格為 130.70 美元，最後交易價格為 128.76 美元。在交易過程中，約有 501,417 股易手，較平均每日交易量 1,355,177 股下降了 63%。該股票此前收盤價為 120.55 美元。</p>
</div><ul>
<li>Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May</li>
</ul>
<div class="lb-trans"><ul>
<li>中型股的奇蹟：三隻在五月份超越銷售預期的股票</li>
</ul>
</div><p>TMDX has been the topic of a number of other research reports. Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of TransMedics Group in a report on Tuesday, June 17th. Oppenheimer raised their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, June 17th. Morgan Stanley raised their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the company an &#34;equal weight&#34; rating in a report on Friday. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, July 15th. Finally, Piper Sandler reaffirmed an &#34;overweight&#34; rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $123.00.</p>
<div class="lb-trans"><p>TMDX 已經成為其他多份研究報告的主題。Needham &amp; Company LLC 在 6 月 17 日的報告中重申了對 TransMedics Group 股票的 “持有” 評級。Oppenheimer 在 6 月 17 日的報告中將 TransMedics Group 的股票目標價從 130.00 美元上調至 150.00 美元，並給予該公司 “跑贏大盤” 的評級。摩根士丹利在週五的報告中將 TransMedics Group 的股票目標價從 115.00 美元上調至 123.00 美元，並給予該公司 “同等權重” 的評級。Canaccord Genuity Group 在 7 月 15 日的報告中將 TransMedics Group 的股票目標價從 129.00 美元上調至 142.00 美元，並給予該公司 “買入” 的評級。最後，Piper Sandler 在 6 月 4 日的報告中重申了 “超配” 評級，並將 TransMedics Group 的股票目標價設定為 145.00 美元（之前為 125.00 美元）。三位研究分析師對該股票給予了持有評級，六位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為 123.00 美元。</p>
</div><p>Get <strong>TransMedics Group</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>TransMedics Group</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Report on TMDX</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 TMDX 的最新報告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻在 2025 年表現優異的醫療技術股票</li>
</ul>
</div><p>In other TransMedics Group news, Director David Weill sold 732 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director owned 12,134 shares in the company, valued at approximately $1,503,159.92. This trade represents a 5.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,418 shares of company stock worth $1,512,613. Company insiders own 7.00% of the company's stock.</p>
<div class="lb-trans"><p>在其他 TransMedics Group 的新聞中，董事 David Weill 在 5 月 23 日的交易中出售了 732 股該公司的股票。股票以平均價格 123.88 美元出售，總交易額為 90,680.16 美元。出售後，該董事在公司中持有 12,134 股，價值約為 1,503,159.92 美元。這筆交易代表了其持股比例的 5.69% 下降。該交易已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。此外，內部人士 Anil P. Ranganath 在 6 月 9 日的交易中出售了 686 股該公司的股票。股票以平均價格 139.80 美元出售，總交易額為 95,902.80 美元。出售後，該內部人士在公司中持有 13,955 股，價值約為 1,950,909 美元。這筆交易代表了其持股比例的 4.69% 下降。該出售的披露信息可以在這裏找到。在過去 90 天內，內部人士已出售 12,418 股公司股票，價值 1,512,613 美元。公司內部人士持有公司股票的 7.00%。</p>
</div><h2>Institutional Investors Weigh In On TransMedics Group</h2>
<div class="lb-trans"><h2>機構投資者對 TransMedics Group 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Opal Wealth Advisors LLC bought a new stake in shares of TransMedics Group during the second quarter valued at approximately $26,000. Sound Income Strategies LLC bought a new stake in shares of TransMedics Group during the second quarter valued at approximately $48,000. NBC Securities Inc. bought a new stake in shares of TransMedics Group during the first quarter valued at approximately $25,000. Smartleaf Asset Management LLC raised its position in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after buying an additional 135 shares during the last quarter. Finally, Atlas Capital Advisors Inc. bought a new stake in shares of TransMedics Group during the fourth quarter valued at approximately $31,000. Institutional investors own 99.67% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近調整了對該股票的持有。Opal Wealth Advisors LLC 在第二季度購買了 TransMedics Group 的新股份，價值約為 26,000 美元。Sound Income Strategies LLC 在第二季度購買了 TransMedics Group 的新股份，價值約為 48,000 美元。NBC Securities Inc.在第一季度購買了 TransMedics Group 的新股份，價值約為 25,000 美元。Smartleaf Asset Management LLC 在第一季度將其在 TransMedics Group 的持股比例提高了 44.3%。Smartleaf Asset Management LLC 現在持有 440 股該公司的股票，價值 30,000 美元，此前在上個季度又購買了 135 股。最後，Atlas Capital Advisors Inc.在第四季度購買了 TransMedics Group 的新股份，價值約為 31,000 美元。機構投資者持有公司 99.67% 的股票。</p>
</div><h2>TransMedics Group Stock Performance</h2>
<div class="lb-trans"><h2>TransMedics Group 股票表現</h2>
</div><ul>
<li>3 High-Growth Stocks Traders Love and Investors Should Watch</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻交易者喜愛的高增長股票，投資者應關注</li>
</ul>
</div><p>The stock has a market cap of $4.44 billion, a P/E ratio of 67.48 and a beta of 2.09. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The firm's 50-day moving average price is $124.51 and its 200-day moving average price is $95.50.</p>
<div class="lb-trans"><p>該股票的市值為 44.4 億美元，市盈率為 67.48，貝塔值為 2.09。該公司的債務與股本比率為 1.61，流動比率為 9.86，速動比率為 9.17。該公司的 50 日移動平均價格為 124.51 美元，200 日移動平均價格為 95.50 美元。</p>
</div><p>TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. During the same quarter in the previous year, the business posted $0.35 earnings per share. TransMedics Group's quarterly revenue was up 37.7% on a year-over-year basis. Sell-side analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>TransMedics Group（納斯達克代碼：TMDX - 獲取免費報告）最近在 7 月 30 日宣佈了其季度財報。該公司報告每股收益為 0.92 美元，超出市場共識預期的 0.48 美元，超出幅度為 0.44 美元。TransMedics Group 的淨利潤率為 13.49%，股本回報率為 28.02%。該公司季度收入為 1.5737 億美元，而分析師預期為 1.4664 億美元。去年同期，該公司每股收益為 0.35 美元。TransMedics Group 的季度收入同比增長 37.7%。賣方分析師預計 TransMedics Group, Inc.在當前財政年度將發佈 1 美元的每股收益。</p>
</div><h2>About TransMedics Group</h2>
<div class="lb-trans"><h2>關於 TransMedics Group</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.</p>
<div class="lb-trans"><p>TransMedics Group, Inc.是一家商業階段的醫療技術公司，致力於為美國及國際上的終末期器官衰竭患者轉變器官移植治療。該公司提供器官護理系統（OCS），這是一種便攜式器官灌注、優化和監測系統，利用其專有和定製技術在人體外複製接收器官的近生理條件。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than TransMedics Group</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>3 Surprising Earnings Winners Changing Their Market Narrative</li>
<li>How to Invest in the FAANG Stocks</li>
<li>How 2 Deals in 48 Hours Changed Everything for Joby Aviation</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>5 Stocks Shaping Tomorrow’s World</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 TransMedics Group</li>
<li>這些液化天然氣股票是否準備迎來反彈？</li>
<li>三個令人驚訝的盈利贏家改變了他們的市場敍事</li>
<li>如何投資 FAANG 股票</li>
<li>48 小時內的兩筆交易如何改變了 Joby Aviation 的一切</li>
<li>深入瞭解買賣差價</li>
<li>五隻塑造明天世界的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in TransMedics Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 TransMedics Group 嗎？</h2>
</div><p>Before you consider TransMedics Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 TransMedics Group 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 TransMedics Group 並不在名單上。</p>
</div><p>While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 TransMedics Group 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

TransMedics 集團（NASDAQ:TMDX）股價在分析師上調評級後上漲了 6.8%